Actinium Announces Completion of Enrollment of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy
Stock Information for Actinium Pharmaceuticals Inc. (Delaware)
Loading
Please wait while we load your information from QuoteMedia.